Clinical Trials Browser

Completed × NVP-BKM120 × Lymphoid × Clear all

NCT02340780 2023-08-22

Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

Phase 2 Completed

14 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02756247 2022-10-10

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Phase 1 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02049541 2022-06-30

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Phase 1 Completed

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01719250 2018-10-09

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase EARLY_PHASE1 Completed

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT01693614 2018-09-28

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Phase 2 Completed

72 enrolled 15 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02301364 2017-10-19

Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Phase 2 Completed

4 enrolled 11 charts

Lymphoma, Recurrence

NCT01396499 2016-11-01

Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias

Phase 1 Completed

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma